Aspire Biopharma Holdings, Inc.(ASBP)Earnings, Financials & Key Ratios
ASBP•NASDAQ
$0.19
$9M mkt cap·Price updated May 6, 2026
AboutAspire Biopharma Holdings, Inc. is a biotechnology company specializing in advanced diagnostic solutions and molecular testing. The company focuses on developing high-precision assays for disease detection, leveraging cutting-edge research in genetics and biochemistry to support healthcare and life sciences industries.Show more
- Revenue$0
- EBITDA-$12M-3147.7%
- Net Income-$13M-3391.6%
- EPS (Diluted)-0.26-3233.3%
- Interest Coverage-3.46+91.3%
ASBP Key Insights
Aspire Biopharma Holdings, Inc. (ASBP) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Weak momentum: RS Rating 10 (bottom 10%)
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ASBP Price & Volume
Aspire Biopharma Holdings, Inc. (ASBP) stock price & volume — 10-year historical chart
Loading chart...
ASBP Growth Metrics
Aspire Biopharma Holdings, Inc. (ASBP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-5360.9%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-5077.95%
Return on Capital
10 Years-0.22%
5 Years-0.22%
3 Years-0.22%
Last Year-
ASBP Peer Comparison
Aspire Biopharma Holdings, Inc. (ASBP) competitors in Diagnostics and Omics Tools — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CRBP | 137.7M | 10.99 | -1.86 | -65.76% | 0.01 | |||
 YCBD | 9.19M | 0.91 | -0.84 | -1.5% | -6.51% | -3.64% | 107.70 | |
 XXII | 621.21K | 0.85 | -63.12% | -65.69% | -79.16% | 2.15 | ||
 ATAI | 1B | 4.17 | -4.48 | -1.91% | -51.09% | -96.43% | 0.21 | |
 CMPS | 937.8M | 9.76 | -3.17 | -335.93% | ||||
 MNMD | 2.04B | 20.69 | -10.04 | -55.3% | ||||
 CRON | 999.77M | 2.62 | 64.4% | -4.89% | -0.86% | 0.00 | ||
 CGC | 123.69M | 1.15 | -0.28 | -9.47% | -110.99% | -43.07% | 0.72 |
Compare ASBP vs Peers
Aspire Biopharma Holdings, Inc. (ASBP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ASBP Income Statement
Aspire Biopharma Holdings, Inc. (ASBP) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 1.94K |
| Revenue Growth % | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 1.06K |
| COGS % of Revenue | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 884▲ 0% |
| Gross Margin % | - | - | - | 45.54% |
| Gross Profit Growth % | - | - | - | - |
| Operating Expenses | 596.49K | 358.59K | 3.09M | 20.02M |
| OpEx % of Revenue | - | - | - | - |
| Selling, General & Admin | 421.18K | 286.54K | 3.09M | 19.23M |
| SG&A % of Revenue | - | - | - | - |
| Research & Development | 175.32K | 72.05K | 0 | 823.88K |
| R&D % of Revenue | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | -28K |
| Operating Income | -596.49K▲ 0% | -358.59K▲ 39.9% | -3.09M▼ 761.3% | -20.02M▲ 0% |
| Operating Margin % | - | - | - | -1031436.32% |
| Operating Income Growth % | - | 39.88% | -761.34% | - |
| EBITDA | -596.49K | -358.59K | -11.65M | -28.18M |
| EBITDA Margin % | - | - | - | -1451843.69% |
| EBITDA Growth % | - | 39.88% | -3147.68% | -6676.66% |
| D&A (Non-Cash Add-back) | 0 | 0 | 0 | 1.15M |
| EBIT | -596.49K | -358.59K | -11.65M | -29.33M |
| Net Interest Income | 4.32M | 5.8M | -342.95K | -3.19M |
| Interest Income | 4.32M | 5.81M | 548.68K | 0 |
| Interest Expense | 0 | 8.97K | 891.62K | 3.19M |
| Other Income/Expense | 0 | 0 | -9.45M | -11.72M |
| Pretax Income | -596.49K▲ 0% | -358.59K▲ 39.9% | -12.54M▼ 3396.3% | -31.74M▲ 0% |
| Pretax Margin % | - | - | - | -1635251.26% |
| Income Tax | 626 | 481 | 0 | -1.01K |
| Effective Tax Rate % | -0.1% | -0.13% | 0% | 0% |
| Net Income | -597.12K▲ 0% | -359.07K▲ 39.9% | -12.54M▼ 3391.6% | -31.74M▲ 0% |
| Net Margin % | - | - | - | -1635199.07% |
| Net Income Growth % | - | 39.87% | -3391.64% | -5360.9% |
| Net Income (Continuing) | -597.12K | -359.07K | -12.54M | -31.74M |
| Discontinued Operations | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.01▲ 0% | -0.01▲ 40.0% | -0.26▼ 3233.3% | -0.64▲ 0% |
| EPS Growth % | - | 40% | - | -5077.95% |
| EPS (Basic) | -0.01 | -0.01 | -0.26 | - |
| Diluted Shares Outstanding | 45.94M | 45.94M | 47.64M | 49.53M |
| Basic Shares Outstanding | 45.94M | 45.94M | 47.64M | 49.53M |
| Dividend Payout Ratio | - | - | - | - |
ASBP Balance Sheet
Aspire Biopharma Holdings, Inc. (ASBP) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|
| Total Current Assets | 1.1M | 46.17K | 147.99K | 2.4M |
| Cash & Short-Term Investments | 497.26K | 11.17K | 3.63K | 1.95M |
| Cash Only | 497.26K | 11.17K | 3.63K | 1.95M |
| Short-Term Investments | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 36.5K | 0 |
| Days Sales Outstanding | - | - | - | 1.72K |
| Inventory | 0 | 0 | 0 | 35.44K |
| Days Inventory Outstanding | - | - | - | 3.06K |
| Other Current Assets | 600.49K | 0 | -36.5K | 0 |
| Total Non-Current Assets | 299.08M | 0 | 0 | 0 |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 |
| Fixed Asset Turnover | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 |
| Long-Term Investments | 299M | 0 | 6.67M | 6.67M |
| Other Non-Current Assets | 80.17K | 0 | -6.67M | -6.67M |
| Total Assets | 300.18M▲ 0% | 46.17K▼ 100.0% | 147.99K▲ 220.5% | 2.4M▲ 0% |
| Asset Turnover | - | - | - | 0.00x |
| Asset Growth % | - | -99.98% | 220.5% | 1255.55% |
| Total Current Liabilities | 303.32K | 534.03K | 1.69M | 13.86M |
| Accounts Payable | 0 | 172.77K | 310.22K | 1.06M |
| Days Payables Outstanding | - | - | - | 358.68K |
| Short-Term Debt | 0 | 360.64K | 1.27M | 8.62M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 303.32K | 626 | 111.03K | 3.91M |
| Current Ratio | 3.62x | 0.09x | 0.09x | 0.09x |
| Quick Ratio | 3.62x | 0.09x | 0.09x | 0.09x |
| Cash Conversion Cycle | - | - | - | -353.9K |
| Total Non-Current Liabilities | 10.81M | 0 | 0 | 9.9K |
| Long-Term Debt | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 10.81M | 0 | 0 | 108.49K |
| Total Liabilities | 11.12M | 534.03K | 1.69M | 13.87M |
| Total Debt | 0 | 360.64K | 1.27M | 8.62M |
| Net Debt | -497.26K | 349.46K | 1.26M | 6.68M |
| Debt / Equity | - | - | - | -0.75x |
| Debt / EBITDA | - | - | - | -0.31x |
| Net Debt / EBITDA | - | - | - | -0.24x |
| Interest Coverage | - | -39.99x | -3.46x | -9.19x |
| Total Equity | 289.07M▲ 0% | -487.86K▼ 100.2% | -1.54M▼ 215.7% | -11.47M▲ 0% |
| Equity Growth % | - | -100.17% | -215.68% | -3961.37% |
| Book Value per Share | 6.29 | -0.01 | -0.03 | -0.23 |
| Total Shareholders' Equity | 289.07M | -487.86K | -1.54M | -11.47M |
| Common Stock | 299M | 22K | 22K | 4.95K |
| Retained Earnings | -9.94M | -1.47M | -2.78M | -22.55M |
| Treasury Stock | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
ASBP Cash Flow Statement
Aspire Biopharma Holdings, Inc. (ASBP) cash flow — operating, investing & free cash flow history
| Line item | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|
| Cash from Operations | -142.91K | -653.11K | -2.05M | -2.05M |
| Operating CF Margin % | - | - | - | - |
| Operating CF Growth % | - | -357.02% | -214.6% | -2434.72% |
| Net Income | -597.12K | 4.46M | -12.54M | -31.74M |
| Depreciation & Amortization | 0 | 0 | 0 | 2.02M |
| Stock-Based Compensation | 0 | 0 | 0 | 14.13M |
| Deferred Taxes | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 0 | -5.8M | 9.45M | 6.77M |
| Working Capital Changes | 454.21K | 687.06K | 1.03M | 2.27M |
| Change in Receivables | 400K | 0 | -36.5K | -1.03M |
| Change in Inventory | 0 | 0 | 0 | -35.44K |
| Change in Payables | 102.73K | 0 | 0 | 1.12M |
| Cash from Investing | -4.9M | 284.92M | 13.78M | 0 |
| Capital Expenditures | -4.9M | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - |
| Other Investing | 0 | 284.92M | 0 | 0 |
| Cash from Financing | 4.85M | -284.76M | -11.73M | 5.45M |
| Debt Issued (Net) | -252.91K | 0 | 1.71M | 4.56M |
| Equity Issued (Net) | 1000K | -1000K | -1000K | 8.18K |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | -284.92M | -13.78M | -257.64K |
| Other Financing | 4.11M | 0 | 0 | 880.66K |
| Net Change in Cash | -185.46K▲ 0% | -497.26K▼ 168.1% | 0▲ 100.0% | 1.93M▲ 0% |
| Free Cash Flow | -5.04M▲ 0% | -653.11K▲ 87.0% | -2.05M▼ 214.6% | -3.52M▲ 0% |
| FCF Margin % | - | - | - | -181147.76% |
| FCF Growth % | - | 87.04% | -214.6% | -274.39% |
| FCF per Share | -0.11 | -0.01 | -0.04 | -0.04 |
| FCF Conversion (FCF/Net Income) | 0.24x | 1.82x | 0.16x | 0.11x |
| Interest Paid | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 |
ASBP Key Ratios
Aspire Biopharma Holdings, Inc. (ASBP) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2023 | 2024 | TTM |
|---|---|---|---|
| Return on Equity (ROE) | -0.25% | - | 429.24% |
| Return on Invested Capital (ROIC) | -0.19% | - | 755.25% |
| Gross Margin | - | - | 45.54% |
| Net Margin | - | - | -1635199.07% |
| Debt / Equity | - | - | -0.75x |
| Interest Coverage | -39.99x | -3.46x | -9.19x |
| FCF Conversion | 1.82x | 0.16x | 0.11x |
ASBP Frequently Asked Questions
Aspire Biopharma Holdings, Inc. (ASBP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Aspire Biopharma Holdings, Inc. (ASBP) reported $0.0M in revenue for fiscal year 2024.
Aspire Biopharma Holdings, Inc. (ASBP) grew revenue by 0.0% over the past year. Growth has been modest.
Aspire Biopharma Holdings, Inc. (ASBP) reported a net loss of $31.7M for fiscal year 2024.
Dividend & Returns
Aspire Biopharma Holdings, Inc. (ASBP) had negative free cash flow of $3.5M in fiscal year 2024, likely due to heavy capital investments.
Explore More ASBP
Aspire Biopharma Holdings, Inc. (ASBP) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates